Abstract
•Study design: Utilized the National Readmission Database from 2018-2020. The study included patients over 18 years of age who underwent transcatheter edge-to-edge repair and analyzed readmission for mitral valve (MV) surgery within 180 days.•Readmission rate: Only 1.1% of patients who underwent transcatheter edge-to-edge repair required MV surgery within 180 days.•Mortality and morbidity: In-hospital mortality after MV surgery was 9.7%, with a high incidence of acute kidney injury (51%) and bleeding events (15.7%) among readmitted patients.•Trend over time: The readmission rate for MV surgery significantly declined from 1.8% in 2018 to 0.8% in 2020.•Predictors of readmission: Younger age was identified as an independent predictor of readmission for MV surgery.